Reven Holdings announces first patient dosed in clinical trial evaluating RJX for high-risk COVID-19
WESTMINSTER -- Reven Holdings, Inc. today announced the first patient has been dosed in the Phase I/II trial of RJX in high-risk COVID-19 patients ( ClinicalTrials.gov Identifier: NCT04708340; ... Read More
Thursday April 29, 2021
Reven Pharmaceuticals reports positive results regarding clinical safety and preclinical efficacy of Its COVID-19 drug candidate Rejuveinix
GOLDEN -- Reven Holdings, Inc. today announced publication of a peer-reviewed article in the prestigious medical journal, Frontiers in Pharmacology, Section: Respiratory Pharmacology. In the... Read More
Thursday November 12, 2020
Reven Pharmaceuticals wins FDA nod of IND application for COVID treatment with Rejuveinix
GOLDEN -- Reven today announced the U.S. Food and Drug Administration has approved its Investigational New Drug application in connection with its lead anti-inflammatory/anti-oxidant... Read More
Thursday October 22, 2020
IN Sponsors
Browse
Entrepreneurial by Nature
